Pelthos Therapeutics Inc. (CHRO)
Jul 2, 2025 - CHRO was delisted (reason: merged into PTHS)
13.50
0.00 (0.00%)
Inactive · Last trade price
on Jul 1, 2025
Company Description
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older.
It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025.
Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Pelthos Therapeutics Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | Feb 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Scott Plesha |
Contact Details
Address: 4020 Stirrup Creek Drive Durham, Nevada 27703 United States | |
| Phone | 877 265 8266 |
| Website | pelthos.com |
Stock Details
| Ticker Symbol | CHRO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001919246 |
| CUSIP Number | 171126105 |
| ISIN Number | US1711261057 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Francis Knuettel II, M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Eric Lang M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2025 | 8-K | Current Report |
| May 27, 2025 | DEFM14C | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | PREM14C | Filing |
| May 1, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Jan 15, 2025 | SCHEDULE 13G | Filing |